PubMed COVID-19 Clinical Care

CONCLUSION: This case may indicate that coronavirus disease 2019 was already spreading in Germany as early as December 2019.

CONCLUSIONS: The success of our approach illustrates that pooling information between the ILI and COVID-19 leads to improved forecasting models than individual models for either of the disease.

The emergence of increasingly immunoevasive SARS-CoV-2 variants emphasizes the need for prophylactic strategies to complement vaccination in fighting the COVID-19 pandemic. Intranasal administration of neutralizing antibodies has shown encouraging

Chest computed tomography (CT) has played a valuable, distinct role in the screening, diagnosis, and follow-up of COVID-19 patients. The quantification of COVID-19 pneumonia on CT has proven to be an important predictor of the treatment course and

CONCLUSION: Expansion of virtual post-discharge visits to include all patients and telephone calls did not negatively impact rates of 30-day post-discharge hospital encounters. Offering telehealth options for post-discharge follow-up does not appear

CONCLUSION: The use of saliva to diagnose covid 19 infection is reliable, and its use can be recommended.

It is challenging in COVID-19 patients to determine if the virus is the primary cause of their symptoms, or if it is exacerbating an underlying condition. When the virus is a significant contributing factor, drug therapies must be tailored to the

The identification of the SARS-CoV-2 Omicron variants BA.4/BA.5, BF.7 and BQ.1.1 immediately raised concerns regarding the efficacy of currently used monoclonal antibody therapies. Here we examined the activity of monoclonal antibody therapies and

Exhaled human breath contains a rich mixture of volatile organic compounds (VOCs) whose concentration can vary in response to disease or other stressors. Using simulated odorant-binding proteins (OBPs) and machine learning methods, we designed a

Given the prevalence of low-pathogenic but highly infectious Omicron variants, a cohort study was conducted to assess the response and duration of novel coronavirus-inactivated vaccine-induced antibodies one year after the third dose (day 641). Blood